Bacterial Vaginosis Clinical Trial
Official title:
An Open-label Study to Evaluate Clinical Performance of Gedea Pessary in Adult Women With Bacterial Vaginosis
Verified date | November 2019 |
Source | Gedea Biotech AB |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, single-armed, multi-center study to evaluate clinical performance, tolerability, and safety of Gedea Pessary in 24 adult women with confirmed BV according to fulfillment of at least 3 of the 4 Amsel criteria. On Day 0, patients will have gynecological examination, vaginal samples taken, and will receive the investigational product to be self-administered. Patients will be examined after 7 days with respect to 3 Amsel criteria (the criterion: "pH of vaginal fluid above 4.5" is only included at study inclusion for diagnosis), and if not cured, will receive prolonged treatment for one additional week. Patients will be followed-up by telephone up to 29 days after last treatment. Vaginal samples will be used for confirming diagnosis and microbiome analyzes. Patient questionnaires will be used for assessing BV symptoms, usability, and adverse events (AEs).
Status | Completed |
Enrollment | 24 |
Est. completion date | November 18, 2019 |
Est. primary completion date | October 22, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Adult, post-menarchal, pre-menopausal women aged 18 years or older - Diagnosis of BV according to Amsel's criteria, defined as having at least 3 of the 4 following criteria: 1. Thin, white, yellow, homogenous discharge 2. Clue cells on microscopy (more than 20 percent of epithelial cells) 3. pH of vaginal fluid above 4.5 4. Release of fishy odor "i.e. a positive whiff test" when alkali (10% potassium hydroxide [KOH] solution) is added - Having decisional capacity and providing written informed consent - Negative urine pregnancy test at screening - Refrain from using any intravaginal products (i.e., contraceptive creams, gels, foams, sponges, lubricants, or tampons, etc.) during the study period - Refrain from sexual intercourse or use a condom until Day 7 - Signed informed consent and willing and able to comply with all study requirements Exclusion Criteria: Patients with known or apparent signs of other infectious causes of BV (vulvovaginal candidiasis, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at screening - Anticipated menstruation during the treatment period (Day 0 till Day 7) - Patients who are pregnant or breastfeeding - Patients who were treated for BV within the past 14 days - Patients who are currently receiving antibiotic therapy unrelated to BV or have received antibiotic therapy within the past 14 days - Patients who have used pH-modifying vaginal products within the last 14 days - Patients who have received an investigational drug in a clinical investigation within 30 days prior to screening - Known/previous allergy or hypersensitivity to any product constituent - Any medical condition that in the Investigator's judgments would make the patient unsuitable for inclusion |
Country | Name | City | State |
---|---|---|---|
Sweden | Stortorgets Gynekologmottagning | Helsingborg | |
Sweden | Sophiakliniken | Lund |
Lead Sponsor | Collaborator |
---|---|
Gedea Biotech AB |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical cure rate | Defined as absence of all of the following 3 Amsel criteria: Thin, white, yellow, homogenous discharge Clue cells on microscopy (more than 20% of epithelial cells) Release of fishy odor "i.e. a positive whiff test" when alkali (10% potassium hydroxide [KOH] solution) is added |
Day 7 | |
Secondary | Proportion of patients being negative for each of the 3 Amsel criteria | Defined as absence of the following Amsel criteria: Thin, white, yellow, homogenous discharge Clue cells on microscopy (more than 20% of epithelial cells) Release of fishy odor "i.e. a positive whiff test" when alkali (10% potassium hydroxide [KOH] solution) is added |
Day 7 compared to Day 0 | |
Secondary | Usability, measured by patient questionnaire | General assessment of the treatment [1-10, where 10 is very pleased and 1 is very unpleased] | Day 7 | |
Secondary | Proportion of patients having a recurrence of the BV | Proportion of patients answering [Yes] to the question "Have the symptoms recurred?" | Up to day 42 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03930745 -
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
|
Phase 2 | |
Completed |
NCT02863536 -
A Study of the New Medical Device Polybactum®
|
N/A | |
Completed |
NCT03187457 -
PreFem: "What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?"
|
N/A | |
Recruiting |
NCT02185456 -
Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis
|
Phase 0 | |
Completed |
NCT02150655 -
Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
|
Phase 0 | |
Completed |
NCT01450462 -
Vitamin D and Sexual Health
|
N/A | |
Recruiting |
NCT01558388 -
Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy
|
Phase 4 | |
Not yet recruiting |
NCT00889356 -
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
|
Phase 3 | |
Completed |
NCT01471457 -
Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis
|
Phase 2/Phase 3 | |
Completed |
NCT00545181 -
Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
|
N/A | |
Completed |
NCT00556179 -
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
|
Phase 4 | |
Completed |
NCT02236156 -
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
|
Phase 3 | |
Not yet recruiting |
NCT05434104 -
The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study
|
N/A | |
Completed |
NCT01335373 -
Observational Program Neo-Penotran® Forte
|
N/A | |
Completed |
NCT00752193 -
Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.
|
N/A | |
Active, not recruiting |
NCT00536848 -
The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00510614 -
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
|
Phase 0 | |
Suspended |
NCT00207480 -
Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women
|
Phase 1 | |
Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
Completed |
NCT02905890 -
The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis
|
Phase 4 |